CagriSema Before vs. After: The Honest Visual Guide

CagriSema at a glance:

• Drug class: Combination amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection (combined formulation)
• Typical frequency: once weekly
• Half-life: approximately 7 days for both components
• Receptor target: amylin and GLP-1 receptors

Tracking CagriSema progress is a longer game than most people expect. Here's the timeline that actually plays out for the typical user, week by week.

Week-by-Week Timeline

Weeks 1-4 (titration phase): dose is intentionally non-therapeutic. Side effects (especially GI) are most prominent. Don't judge effectiveness yet.

Weeks 4-8: if you've reached the first therapeutic dose step, appetite changes become noticeable. Early weight loss begins for incretin agents.

Weeks 8-12: a noticeable shift in eating patterns and (for weight-loss indications) early visible change. Trial data put 12-week weight loss around 4-7% of starting body weight on average.

Months 3-6: the majority of total benefit accrues during this window for most users. Average weight loss reaches 8-12% by month 6 for most weight-management products.

Months 6-12: continued progress at a slower pace. Some users plateau around month 9-12. See the plateau guide.

Photos vs. The Scale

The "before and after" framing usually means photographs. Photos often lag the scale by 2-4 weeks because body composition changes (especially around the abdomen) follow weight changes with a delay. Don't be discouraged if the scale moves before the mirror does.

What Doesn't Show in Most Before/Afters

A few effects that show up in users' lives but rarely in marketing photos:

• Reduced "food noise" (intrusive thoughts about food)
• Improved blood pressure
• Improved A1c if applicable
• Lower cardiometabolic risk markers
• Better sleep, often as a downstream effect of weight loss

Maintaining the After

The harder, less-photographed phase is maintenance. Trial extension data show that stopping the medication leads to weight regain — typically 60-70% of lost weight returns within 12 months.

The decision to continue, taper, or stop is best made with a clinician who knows the trajectory.

Common Patterns We See

• Strong responders (top quartile): >20% weight loss for newer incretin therapies
• Average responders: 12-18% weight loss
• Lower responders (bottom quartile): under 8% weight loss; reasonable to consider switching after 6 months at maintenance dose

For CagriSema specifically, phase 2 trials showed mean weight loss around 17% at 32 weeks. redefine phase 3 reported 22.7% weight loss at 68 weeks.

What Affects the Curve

Three factors that consistently change the trajectory:

1. Adherence to titration (skipping dose steps usually means dropping out)
2. Concurrent dietary patterns (not strict diets — just less ultra-processed food)
3. Sleep and stress (both blunt the appetite signal the medication produces)

For the underlying mechanism that drives the timeline, see how CagriSema works.

Bottom Line

Plan for CagriSema as a year-long project, not a 12-week sprint. The bulk of change happens between months 3 and 9.

Frequently Asked Questions

Related Reading

• CagriSema: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• CagriSema Side Effects in 2026: Real Reports, Real Solutions
• What Results Should You Expect from CagriSema? A Practical Guide
• The Real CagriSema Price Tag in 2026 — With and Without Insurance
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.

Photos and personal stories represent individual experiences and are not a guarantee of personal outcome.